Dorzolamide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Ocular HTN; Open-angle glaucoma As 2% soln: Instill 1 drop tid; bid when used w/ a topical β-blocker.
Dosage Details
Ophthalmic
Ocular hypertension, Open-angle glaucoma
Adult: As 2% soln: Instill 1 drop tid; bid when used w/ a topical β-blocker.
Contraindications
Hyperchloraemic acidosis.
Special Precautions
Patient w/ history of renal calculi, pre-existing chronic corneal defects and/or history of intra-ocular surgery. Hepatic and severe renal (CrCl <30 mL/min) impairment. Pregnancy and lactation.
Adverse Reactions
Ocular burning, stinging and discomfort; superficial punctate keratitis, ocular allergic reactions (e.g. conjunctivitis, itching, lid reactions), blurred vision, redness, tearing, dryness, photophobia, transient myopia, eyelid crusting, palpebral reactions, ocular pain, irreversible corneal decompensation, ocular hypotony; acidosis, electrolyte imbalance, systemic allergic reactions (e.g. angioedema, pruritus, bronchospasm, urticaria), dizziness, paraesthesia, throat irritation, dyspnoea, contact dermatitis, bitter taste, headache, nausea, asthenia/fatigue, urolithiasis. Rarely, iridocyclitis.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, and other blood dyscrasias.
Patient Counseling Information
This drug may cause dizziness and visual disturbances, if affected do not drive and operate machinery.
MonitoringParameters
Monitor intraocular pressure periodically.
Drug Interactions
May increase the serum concentration of α-/β-agonists (indirect-acting). May enhance the adverse/toxic effects of other carbonic anhydrase inhibitors.
Action
Description: Dorzolamide reversibly inhibits carbonic anhydrase resulting in reduction of hydrogen ion secretion at renal tubule and increased renal excretion of Na, K, bicarbonate, and water, thus decreasing the production of aqueous humor. It also inhibits carbonic anhydrase in CNS to retard abnormal and excessive discharge from CNS neurons.
Duration: 8-12 hr.
Pharmacokinetics:
Absorption: Systemically absorbed.
Distribution: Accumulates in RBC during chronic admin. Plasma protein binding: Approx 33%.
Metabolism: Converted to N-desethyl metabolite.
Excretion: Via urine, as unchanged drug and metabolites.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 15-30°C. Protect from light.
Disclaimer: This information is independently developed by MIMS based on Dorzolamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in